Unknown

Dataset Information

CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancer.


ABSTRACT:

Background

Colorectal cancer (CRC), the most common cancer type, causes high morbidity and mortality. Patients who develop drug resistance to oxaliplatin-based regimens have short overall survival. Thus, identifying molecules involved in the development of oxaliplatin resistance is critical for designing therapeutic strategies.

Methods

A proteomic screen was performed to reveal altered protein kinase phosphorylation in oxaliplatin-resistant (OR) CRC tumour spheroids. The function of CHK2 was characterised using several biochemical techniques and evident using in vitro cell and in vivo tumour models.

Results

We revealed that the level of phospho-CHK2(Thr68) was elevated in OR CRC cells and in ~30% of tumour samples from patients with OR CRC. We demonstrated that oxalip

SUBMITTER: Hsieh CC 

PROVIDER: S-EPMC9596403 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature